Streetbeat News

Analyst Ratings

UDR

Over the past 3 months, 5 analysts have published their opinion on UDR (NYSE:UDR) stock. The company has an average price target of $51.0, an increase of 9.09% from the previous average price target of $46.75. The analysts' ratings are somewhat bullish, with 3 out of 5 analysts giving a somewhat bullish rating.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 6:01 pm

SLG

SL Green Realty (NYSE:SLG) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 indifferent, and 1 somewhat bearish. Over the past 3 months, 4 analysts have offered 12-month price targets for SL Green Realty, with an average price target of $29.25, a high of $50.00, and a low of $21.00. The average price target has increased by 24.47% over the past month.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 6:00 pm

TFX

Analysts have provided various ratings for Teleflex (NYSE:TFX) within the last quarter, with 1 bullish, 3 somewhat bullish, and 2 indifferent ratings. According to 6 analysts offering 12-month price targets in the last 3 months, Teleflex has an average price target of $283.67, with a high of $330.00 and a low of $261.00. This average price target has increased by 9.1% over the past month.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 6:00 pm

PEGA

Over the past 3 months, 12 analysts have published their opinion on Pegasystems (NASDAQ:PEGA) stock. The average price target for Pegasystems has increased by 13.32% from the previous average price target of $47.14 to $53.42.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 6:00 pm

BMY

Analysts have provided mixed ratings for Bristol-Myers Squibb (NYSE:BMY) in the last quarter, with 2 bullish, 4 indifferent, and 3 somewhat bearish. The average 12-month price target for the company is $67.78, a decrease of 0.57% from the previous average of $68.17.

Portfolio Pulse from Benzinga Insights

July 19, 2023 | 6:00 pm

PEN

Baird has initiated coverage on Penumbra Inc (NYSE:PEN) with an Outperform rating and a price target of $375. The analyst notes that Penumbra, a pioneer in aspiration mechanical thrombectomy (MT), is set for robust revenue growth over the next 2-3 years, supported by various factors. The company's proprietary FLASH and BOLT MT systems, launched in 2023, are expected to drive growth. Penumbra has identified multiple large and underpenetrated addressable market opportunities in vascular and neuro segments. The company's ongoing clinical trials hold the potential to accelerate MT adoption and expand the addressable markets.

Portfolio Pulse from Vandana Singh

July 19, 2023 | 5:59 pm

META

Truist Securities analyst Youssef Squali has maintained a Buy rating on Meta Platforms Inc (NASDAQ:META) and raised the price target from $265 to $340. The analyst is positive on Meta due to a recovery in ad spending and positive user engagement. The company's focus on operating efficiencies and investment in AI/ML are also seen as positive. However, despite initial success, Threads, Meta's new platform, has seen a decrease in daily users and time spent per user.

Portfolio Pulse from Anusuya Lahiri

July 19, 2023 | 5:53 pm

T

AT&T has addressed concerns about lead exposure, asserting that it has maintained a safe working environment for decades. The company clarified that less than 10% of its footprint is lead-sheathed, and a small minority will need to be removed. The cost of removal is not expected to exceed $20k per mile, with the total exposure estimated to be between $2 billion and $20 billion. The company's shares traded higher by 8.36% following the announcement. However, AT&T has been downgraded to Hold from Buy by Argus analyst Joseph Bonner due to potential environmental risks.

Portfolio Pulse from Anusuya Lahiri

July 19, 2023 | 5:47 pm

WAL

Wedbush has maintained an Outperform rating on Western Alliance Bancorporation and raised its price target from $45 to $50. This has led to a rise in the trading of Western Alliance Bancorporation shares.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2023 | 5:45 pm

IRTC

Baird has initiated coverage on iRhythm Technologies Inc (IRTC) with an Outperform rating and a $130 price target. The company's ZioService is expected to dominate the ambulatory cardiac monitoring (ACM) sector. The analyst predicts a 20% growth outlook over the next five years, with IRTC's PCP volumes growing at a ~25% CAGR. The company plans to expand into multiple international markets, with international revenue expected to represent ~8% of total company revenue by 2027. However, IRTC received a Warning Letter from the FDA regarding non-conformities to medical device regulations, which could impact the stock.

Portfolio Pulse from Vandana Singh

July 19, 2023 | 5:41 pm